Big pharma, M&A, Partnering, Pharma

Spectrum Pharmaceuticals announces m&a deal with Allergan to reacquire rights for apaziquone

Posted on 01 February 2013

Tags: , , ,

Big biotech, Spectrum Pharmaceuticals, is in a m&a deal with Allergan.

In the light of this m&a deal, Spectrum has reacquired development and commercialization rights for apaziquone in the United States, Europe and other territories pursuant to an agreed-upon restructuring of Spectrum’s collaboration with Allergan.

In exchange of this m&a deal, Allergan will receive a royalty on future revenue.

Apaziquone is an anticancer agent being developed for the treatment of non-muscle invasive bladder cancer as a single instillation following transurethral resection of bladder tumor .

Spectrum also announced that a scheduled meeting with the U.S. Food & Drug Administration (FDA) was held last month to discuss the results from the Company’s Phase 3 clinical trials.

For further deal information visit Current Agreements (subscription required)

Related

Reports: Merger and Acquisition Terms and Agreements

  Partnering Deals and Alliances with Big Pharma

  Royalty Financing Partnering Terms Agreements

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply